Acute cardiac care & resuscitation
Sodium-glucose cotransporter-2 inhibitors compared with glucagon-like-peptide-1 receptor agonists and out-of-hospital cardiac arrest in type 2 diabetes: a nationwide nested case-control study
Main finding · OHCAResult — go to the resultAdjusted odds ratio 0.76 95% CI 0.58–0.99Authors' conclusion
Use of SGLT-2i is associated with a reduced risk of OHCA compared with use of GLP-1a in type 2 diabetes.
Study context
- Population
- Individuals with T2DM in Denmark, 2013–2019; cases out-of-hospital cardiac arrest (OHCA) from presumed cardiac causes3,618 cases · 18,090 matched controls
- Comparison
- SGLT-2i vs GLP-1a
- Outcome
- OHCA
Methodological detailsnationwide, Danish registries, matched on age, sex and index date (1:5)
- Nationwide
- Danish registries
- Matched on age, sex and index date (1:5)
Main finding
As reported in the abstract
Adjusted odds ratio
0.76
95% CI 0.58–0.99
SGLT-2ivs GLP-1a
adjusted OR 0.76 (95% CI 0.58–0.99)
Observational data: associations, not effects.
Further findings
OHCA by sex, pre-existing cardiac disease, HF, DM duration, CKD (subgroups)
- Adjusted OR did not vary significantly by subgroup
- Interaction P: sex 0.461; cardiac disease 0.762; HF 0.891; DM duration 0.101; CKD 0.894
Original publication
Sodium-glucose cotransporter-2 inhibitors compared with glucagon-like-peptide-1 receptor agonists and out-of-hospital cardiac arrest in type 2 diabetes: a nationwide nested case-control study. Eur Heart J Cardiovasc Pharmacother. Published 12 May 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →